Diary-based Study on the Course of Hormone-withdrawal Migraines

Migraine Clinical Trial

Official title:

Single Centered Diary-based Study to Identify Course and Characteristics of Hormone Withdrawal Headaches/Migraines in Users of Combined Hormonal Contraceptives

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04012593
• Other study ID #: 2016-01791
• Status: Completed
• Start date: January 2017
• Est. completion date: August 31, 2019

Study information

• Verified date: July 2019
• Source: University of Zurich
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Single centered diary-based study to identify course and characteristics of hormone withdrawal headaches/migraines in users of combined hormonal contraceptives Objectives of the Research Project: to identify the course and characteristics of hormone withdrawal headaches/migraines in users of combined hormonal contraceptives (CHC)

Description:

Participant recruitment is performed through advertisement placed in University Zürich (USZ) online. Advertisement in offices of neurologists and headache specialists, homepage of the Swiss headache society.

Interested women contact the investigators via email and are called back by one of the study doctors or students within 1 day from Monday-Friday. This phone call is thought to inform the women about the study in more detail and for the investigators to check eligibility. During this call the participants are informed about the study procedure and can ask any question. Here most important points are use of a CHC in a 21/7 regimen, regular (at least once on two months) withdrawal migraine/headaches, intention to continue the use of the contraceptive for 3 more months.

If the participants decide to participate, inclusion and exclusion criteria are checked. If women are applicable they receive the consent form and the study information with an envelope for return. If more questions come up the investigators are available per email and phone for answers. If a patient doesn't return the consent form the investigator will delete the personal data, which collected before. Only the year of birth will be noted in the personal data.

After consent participants receive headaches diaries (with mail /post) and a prepaid envelope (for return). Participants are also offered the option to return their diaries electronically via email to the study doctor. Furthermore participants receive in a second phone contact instructions, how to fill in the headache diary and the day of study start (first day of the next pill package).

Headache diaries should be returned monthly (per email or post) and are conducted for 3 pill cycles.

If complete headache diaries are not returned participants will be contacted per email after 1 week to remind the participants. If this email is not being answered within another week a phone contact will take place to identify potential reasons for noncompliance or withdrawal of consent or drop out.

Observation period 3 pill cycles : 3 times 28 days

Outcomes of the Research Project:

• Daily number of headaches and migraine in each day of the observation cycle.and during the Hormone-free interval (HFI)

• First day of migraine in the pill-free interval

• Start of migraine in relation to withdrawal bleeding

• Start of and number of prolonged migraines >24 hours in the pill-free interval and the phase of hormone intake.

• Pain intensity in the pill-free interval in comparison to the pill-phase

• Number of rescue medications/ migraine day during HFI and during pill intake

• efficacy of the medications (did medication stop the attack and did the attack return after maximal 8 hours)

• Within patient variability of the first migraine day in the HFI.

Statistical Methodology:

• Primary and secondary endpoints will be calculated as frequencies and percentages.

• For comparison the number of prolonged attacks during pill use and the HFI prolonged attacks per day of the observation interval are calculated and thereafter chi-square test for comparisons is used .

• Software programme is used for data analyses.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 47
• Est. completion date: August 31, 2019
• Est. primary completion date: April 15, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Premenopausal women

• Age 18-50 years

• Use of combined hormonal contraceptives 21/7 regimen

• Suffering from headache/migraine in the HFI.

• Women are allowed to use their normal headache medications

Exclusion Criteria:

• Withdrawal of consent

• incomplete diaries

• pregnancy

• migraine/headache in only 1 cycle

• inability to follow procedures (e.g. due to psychological disorders or dementia), insufficient knowledge of project language).

Related Conditions & MeSH terms

• Migraine
• Migraine Disorders

Intervention

Behavioral:
• Diary

Locations

Country	Name	City	State
Switzerland	Universitätsspital Zürich	Zürich

Sponsors (1)

Lead Sponsor	Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Migraine in the pill-free interval	Migraine at each day of the pill-free interval	up to 3 months
Secondary	First migraine day	First day of migraine in the pill-free interval	up to 3 months
Secondary	migraine episodes	Start of migraines >24 hours in the pill-free interval	up to 3 months